If approved, the drug could have huge benefits for patients as they could self-administer their therapy from home. Takeda has announced topline data from the Phase III VISIBLE 2 clinical trial, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis. On March 27, 2023, Takeda Pharmaceutical announced that the ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Inflammatory bowel disease (IBD) patients who are resistant to or cannot tolerate conventional treatment now have a more flexible biologics option available to them. Entyvio (generic name vedolizumab) ...

FDA approves Entyvio, an injection to treat adult patients with moderate to severe ulcerative colitis and Crohn's disease. FDA has approved Entyvio (vedolizumab), an injection to treat adult patients ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...